Neuromuscular Disease Unit / ALS Clinic St. Gallen

Kantonsspital St. Gallen

The ALS Clinic in St. Gallen is the major referral center for ALS patients in Switzerland.

st. gallen
Kantonsspital St. Gallen

We offer multidisciplinary patient care to 200 patients from all over Switzerland. Patients are seen on a regular basis, usually every three months. In addition, we are engaged in numerous research projects. These cover a broad spectrum reaching from quality of life research to genetic research. Most of the projects are collaborations with other ALS/MND centers. Clinical neurophysiology is a corner stone in our routine clinical practice and also in some research projects. Our mission is to provide holistic care to ALS patients and caregivers and to contribute to ALS research.

Contact
Location
Rorschacher Strasse, St. Gallen, Switzerland

Our Specialists

Markus Weber

Professor of Neurology

Markus Weber is Professor of Neurology in Kantonsspital St. Gallen

Markus Weber
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more